

AMENDMENT

Please amend the application as follows:

IN THE CLAIMS

A. Please cancel claims 50-55 and 58-63 without prejudice to future prosecution.

B. Please add the following new claims.

- 64.⁶⁶ (New) An antibody which binds to a polypeptide of a mammalian Del-1 or a fragment of the polypeptide of said mammalian Del-1.
- 65.⁶⁷ (New) The antibody of claim 64 wherein the antibody specifically binds to an epitope of said mammalian Del-1.
- 66.⁶⁸ (New) The antibody of claim 64 wherein the antibody is selected from a group consisting of single chain, chimeric, Fab, F(ab')₂, and a fragment produced by an Fab expression library.
- 67.⁶⁹ (New) The antibody of claim 64 wherein the antibody is a polyclonal antibody.
- 68.⁷⁰ (New) The antibody of claim 64 wherein the antibody is a monoclonal antibody.
- 69.⁷¹ (New) The antibody of claim 64 wherein said mammalian Del-1 is a human Del-1.
- 70.⁷² (New) The antibody of claim 69, wherein said human Del-1 comprises the amino acid sequence as shown in SEQ ID NO 30.
- 71.⁷³ (New) The antibody of claim 70 wherein the antibody specifically binds to an epitope of the polypeptide of said human Del-1.
- 72.⁷⁴ (New) The antibody of claim 69, wherein said human Del-1 comprises the amino acid sequence as shown in SEQ ID NO 31.
- 73.⁷⁵ (New) The antibody of claim 72 wherein the antibody specifically binds to an epitope of said human Del-1.
- 74.⁷⁶ (New) The antibody of claim 69 wherein the antibody is selected from a group consisting of single chain, chimeric, Fab, F(ab')₂, and a fragment produced by an Fab expression library.
- 75.⁷⁷ (New) The antibody of claim 69 which is a polyclonal antibody.
- 76.⁷⁸ (New) The antibody of claim 69 which is a monoclonal antibody.

17. ⁷⁹ (New) A method of using the antibody in claim 69 wherein the antibody is used to competitively inhibit the binding of said human Del-1 to alpha V beta 3.
18. ⁸⁰ (New) A method of using the antibody in claim 69 wherein the antibody is used to inhibit the activity of said human Del-1.
19. ⁸¹ (New) A method of using the antibody in claim 69 wherein the antibody is used to isolate a cell expressing said human Del-1.
20. ⁸² (New) A method of using the antibody in claim 69 wherein the antibody is used to detect a cell expressing said human Del-1.
21. ⁸³ (New) A method of using the antibody in claim 69 wherein the antibody is used to competitively inhibit the binding of a molecule to said human Del-1.
22. ⁸⁴ (New) A method of using the antibody in claim 69 wherein the antibody is linked to a cytotoxic agent.
23. ⁸⁵ (New) A method of using the antibody in claim 69 wherein the antibody is linked to a radioisotope.
- P. 1126 24. ⁸⁶ (New) A method of using the antibody in claim 69 wherein the antibody is anchored on a solid support.

IN THE SPECIFICATION

1. On page ii, lines 27-31, please delete the paragraph on priority information and insert the following in its place:

This is a divisional application of United States Patent Application Serial NO. 08/659,235, filed June 5, 1996 [(allowed)], now U.S. Patent No. 5,877,281, issued on March 2, 1999, which is a continuation-in-part of United States Patent Application Serial No. 08/480,229, filed June 7, 1995 [(allowed)], now U.S. Patent No. 5,874,562, issued on February 23, 1999, each of which is incorporated herein in its entirety.